centers on disrupting the activation of mast cells and basophils, which play a key role in allergic responses.

Excellergy advances a pipeline of therapeutic candidates, including investigational molecules intended to provide sustained control of allergic conditions by targeting underlying immune mechanisms. The organization conducts preclinical and clinical development activities to evaluate safety, biological activity, and treatment potential.